CD38 and plasma cell myeloma: Several monoclonal antibodies have been shown to induce ADCC mediated by NK cells and frequently studied examples are trastuzumab for Her2 expressing tumors, cetuximab (anti-EGFR), rituximab or obinutuzumab (anti-CD20) for B cell malignancies, daratumumab (anti-CD38) or elotuzumab (anti-CS1) in multiple myeloma (reviewed in [31]).